Core Viewpoint - The company reported a significant decline in revenue and an increase in net losses for the third quarter of 2025, indicating ongoing financial challenges and the need for strategic transformation [1] Financial Performance - For the third quarter, the company's revenue was 274 million, a year-on-year decrease of 38.4% [1] - The net loss for the third quarter improved slightly to 31.12 million from a loss of 51.25 million in the same period last year [1] - Year-to-date revenue for 2025 was 857 million, down 39.6% compared to the previous year [1] - The net loss for the year-to-date period increased to 87.24 million from a loss of 56.03 million in the previous year [1] - Total assets as of the end of the third quarter were 2.09 billion, a decrease of 26.1% from the end of the previous year [1] - The company's net assets increased by 16.8% to 1.091 billion compared to the end of the previous year [1] Strategic Focus - The company is focusing on core business areas and optimizing its operational structure while undergoing a strategic transformation towards medical intelligence [1] - The decline in revenue and gross profit was attributed to the transfer of equity in some subsidiaries during the reporting period [1] - To enhance profitability, the company has strengthened cost control, resulting in a combined reduction of 18.54% in sales, management, and financial expenses [1] - The report indicated that the company recognized credit impairment losses, which impacted operating profits [1] Business Operations - The company's main business includes medical supply chain services and the research and sales of related products, aiming to provide efficient medical services and solutions to clients [1] - The company plans to continue optimizing its business structure and upgrading its operations to respond to market changes and industry challenges [1]